FLT3 (F691L/D835Y)
Sign in to save this workspaceFLT3 · Variant type: compound · HGVS: p.F691L;p.D835Y
Components
p.F691Lp.D835Y
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 2 | Gilteritinib | 99.8% | 0.2% | 88.97 |
| 3 | Sunitinib | 99.2% | 0.8% | 91.73 |
| 4 | Entrectinib | 97.1% | 2.9% | 93.69 |
| 5 | Selpercatinib | 96.2% | 3.8% | 96.72 |
| 6 | Pacritinib | 95.4% | 4.6% | 88.64 |
| 7 | Defactinib | 93.9% | 6.1% | 92.68 |
| 8 | Fedratinib | 88.4% | 11.6% | 96.21 |
| 9 | Avapritinib | 87.7% | 12.3% | 97.73 |
| 10 | Rabusertib | 86.0% | 14.0% | 98.74 |
| 11 | Alpelisib | 71.1% | 28.9% | 97.22 |
| 12 | Tenalisib | 59.5% | 40.5% | 97.98 |
| 13 | Darovasertib | 52.9% | 47.1% | 96.99 |
| 14 | Tivozanib | 52.6% | 47.4% | 92.42 |
| 15 | Lazertinib | 50.8% | 49.2% | 97.47 |
| 16 | Canertinib | 50.2% | 49.8% | 96.49 |
| 17 | Paxalisib | 31.7% | 68.3% | 99.75 |
| 18 | Neratinib | 29.6% | 70.4% | 93.18 |
| 19 | Erlotinib | 29.2% | 70.8% | 99.75 |
| 20 | Palbociclib | 27.6% | 72.4% | 98.75 |
| 21 | Futibatinib | 25.2% | 74.8% | 98.48 |
| 22 | Abrocitinib | 21.7% | 78.3% | 99.50 |
| 23 | Pirtobrutinib | 19.6% | 80.4% | 99.49 |
| 24 | Abemaciclib | 19.5% | 80.5% | 91.48 |
| 25 | Vandetanib | 19.0% | 81.0% | 95.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 100.0% | 97.6% | +2.4% |
| Gilteritinib | 99.8% | 99.2% | +0.6% |
| Sunitinib | 99.2% | 98.7% | +0.4% |
| Entrectinib | 97.1% | 96.1% | +1.0% |
| Selpercatinib | 96.2% | 96.1% | +0.0% |
| Pacritinib | 95.4% | 93.6% | +1.8% |
| Defactinib | 93.9% | 94.6% | -0.7% |
| Fedratinib | 88.4% | 98.2% | -9.8% |
| Avapritinib | 87.7% | 88.6% | -0.9% |
| Rabusertib | 86.0% | — | — |
| Alpelisib | 71.1% | — | — |
| Tenalisib | 59.5% | — | — |
| Darovasertib | 52.9% | — | — |
| Tivozanib | 52.6% | — | — |
| Lazertinib | 50.8% | — | — |
| Canertinib | 50.2% | 86.3% | -36.1% |
| Paxalisib | 31.7% | — | — |
| Neratinib | 29.6% | — | — |
| Erlotinib | 29.2% | — | — |
| Palbociclib | 27.6% | — | — |
| Futibatinib | 25.2% | — | — |
| Abrocitinib | 21.7% | — | — |
| Pirtobrutinib | 19.6% | — | — |
| Abemaciclib | 19.5% | — | — |
| Vandetanib | 19.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 26.8ms